Translate page

CD5038 Conversations tile 27x12813946March 2022 - The iCMLf Conversations on CML have developed into one of our key educational programs. So far, we have hosted 24 live expert discussions with 37 experts, covering a wide a range of topics around CML management.

All expert discussions are now available to view on-demand on the iCMLf website and the presentations have been viewed more than 8,000 times so far.

We are also delighted to share that we will continue with these expert discussions this year. Over the next couple of months we will be hosting monthly live webinars with renowned experts in the field that cover a wide range of relevant topics for your clinical practice. Be excited!

Oliver HantschelMarch 2022 - The iCMLf awards the 2022 Rowley Prize to Professor Oliver Hantschel, for his scientific research on structural biochemistry of tyrosine kinase oncoproteins that helped to describe novel targetable pathways in the pathophysiology of BCR-ABL. The Rowley Prize is awarded to celebrate people who have made outstanding lifetime contributions to the understanding of the biology of CML.

Andreas Hochhaus

March 2022 - We are delighted to announce Professor Andreas Hochhaus, Head of the Department of Hematology and Medical Oncology at Jena University Hospital as the 2022 Goldman Prize recipient. He receives the prize in recognition of his outstanding clinical leadership in CML and for his lifelong contributions to the optimization of CML therapy – through his work on mechanisms of resistance and stem cell persistence, through leading clinical studies and through the development of clinical recommendations. The annual Goldman Prize awarded in honour of Professor John Goldman, acknowledges outstanding lifetime contributions to the management of patients with CML.

Collage iCMLf Prize 2022

March 2022 - This year, the iCMLf Directors and Advisors have selected two powerful voices for patients with CML as recipients for the iCMLf Prize. Giora Sharf (Israel) and Jan Geissler (Germany) have used the experience of their own diagnosis to help other patients. They have tirelessly advocated for the needs of patients with CML across the world over the past decades. The iCMLf Prize recognizes outstanding contributions to the improvement of CML treatment in low- and middle-income countries. As giants in patient advocacy around the world, Jan and Giora are worthy recipients of this award.

RDD 2022 facebook banner Kopie February 2022 - Along with many other organisations, today we show our colours and support Rare Disease Day 2022.

There are over 300 million people living with a rare disease worldwide –
A global rare disease community with a powerful voice together.

Our voice goes especially for people living with CML around the world. With an incidence of between 1 and 2 people per 100,000 people annually, CML is a rare disease. But with the increasing prevalence of CML, a concerted global effort working towards a cure is imperative.

Remission Alliance RGBWhile a cure for CML remains the ultimate goal, treatment free remission (TFR) is often the treatment target for those on TKI therapy. Still, with around 50-60% of people achieving sustained TFR there is much room for improvement.
The iCMLf TFR Alliance has now evolved into a global network of 41 collaborators from 21 countries aiming to enhance successful TFR attempts for people with CML.

In 2021 the TFR Alliance began the process to establish an International TFR Registry that will be an optimal way to study clinically (and pharmaco-economically) important research questions on treatment-free remission.

To set up the registry, initial seed funding from the iCMLf was awarded to the Swedish CML Registry Group following a call for proposals. In August, a first meeting was held to define priorities for the TFR Registry and a survey to define the registry parameters and outcomes was sent out to the community. We meet in February to finalise the registry priorities and move into set up phase.

Learn more about the TFR Registry and how to get involved...